Omnicell To Buy FDS Amplicare For $177 Million In Cash - Quick Facts

Omnicell, Inc. (OMCL), a provider of medication management solutions and adherence tools for health systems and pharmacies, announced Monday it has entered into a definitive agreement with pharmacy software solutions provider FDS Amplicare to acquire its business for total aggregate cash consideration of $177 million, subject to customary adjustments.

The acquisition will add a comprehensive and differentiated suite of financial management, analytics, and population health solutions to Omnicell's EnlivenHealth division. It will broaden the offerings that will help pharmacies to measurably improve patient health outcomes while enabling new clinical services and expanding growth and profitability opportunities.

The FDS Amplicare acquisition is expected to enable Omnicell and its EnlivenHealth division to offer a wider array of proven digital technologies, SaaS solutions, and tech-enabled services that empower pharmacists to practice at the top of their license.

The intended result is that pharmacists can spend more quality time with patients, providing value-added, revenue-generating healthcare services such as vaccinations, point-of-care testing, and medication therapy management (MTM) counseling.

Omnicell will use cash available on its balance sheet to fund the transaction. Upon closing, the transaction is expected to be immediately accretive to Omnicell's adjusted EBITDA and adjusted earnings per share.

The transaction, which is expected to close in the second half of 2021, is subject to Hart-Scott-Rodino clearance and the satisfaction of other customary closing conditions.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT